PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 12197593-1 2002 In recent years there has been renewed interest in beating heart surgery using the ultra-active and selective beta1-blocker, esmolol. esmolol 125-132 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 110-115 14517655-0 2002 An antagonistic effect of esmolol on beta-3 adrenoceptor in brown adipose tissue in rats. esmolol 26-33 adrenoceptor beta 3 Rattus norvegicus 37-56 11602813-2 2001 Celiprolol is a beta 1 -receptor blocker with vasodilating properties, whereas esmolol is an ultra-short-acting beta 1 -blocker. esmolol 79-86 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 112-118 11736772-2 2001 Thirty-one patients received an infusion of esmolol 0-300 microg x kg(-1) x min(-1) and 37 patients comprised the control group. esmolol 44-51 CD59 molecule (CD59 blood group) Homo sapiens 76-82 11576054-9 2001 High bolus dose (200 mg) of esmolol produced a considerable decrease in DBP [WMD 10.1 mmHg (95% CI: 7.3 to 12.8)]. esmolol 28-35 D-box binding PAR bZIP transcription factor Homo sapiens 72-75 11910689-8 2001 A significant decrease of the mean arterial pressure (-11%) and of the prp (product systolic arterial pressure heart rate) have been raised during the mls, in the group esmolol, whereas the variations of the cardiac frequency were comparable. esmolol 169-176 prion protein Homo sapiens 71-74 9605365-2 1998 METHODS: In this double-blind randomized study esmolol, an ultrashort-acting beta1-adrenoceptor antagonist was compared with physiological saline (control) in 28 patients undergoing laparoscopic surgery in standardized 1 MAC isoflurane anaesthesia. esmolol 47-54 adrenoceptor beta 1 Homo sapiens 77-95 10910502-3 2000 Cholinesterases such as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) hydrolyze and inactivate several anesthetic drugs, including cocaine, heroin, esmolol, local ester anesthetics, and neuromuscular blocking drugs. esmolol 164-171 acetylcholinesterase (Cartwright blood group) Homo sapiens 46-50 9402661-6 1997 For the clinical study we randomized 60 coronary artery surgery patients to receive either crystalloid cardioplegia (Bretschneider HTK) or selective continuous coronary perfusion via the aortic root with warm esmolol-enriched CPB blood. esmolol 209-216 carboxypeptidase B1 Homo sapiens 226-229 9549747-7 1998 One patient required three intravenous doses of esmolol (10mg each) for a heart rate in excess of 100 beats.min-1. esmolol 48-55 CD59 molecule (CD59 blood group) Homo sapiens 108-113 7502643-5 1995 Selective beta 1 antagonists (i.e., esmolol) may need to be titrated with a direct vasodilator (i.e., nitroprusside) to manage hypertension and tachycardia. esmolol 36-43 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 10-16 9083867-1 1996 BACKGROUND: In the repair of total anomalous pulmonary venous return (TAPVR) under cardiopulmonary bypass, esmolol, ultra short acting beta blocker, was applied to obtain low heart rate and weak ventricular contraction under mild hypothermic cardiopulmonary bypass. esmolol 107-114 TAPVR1 Homo sapiens 70-75 8911063-1 1996 In 2 infants with asplenic syndrome associated with total anomalous pulmonary venous return (TAPVR), a repair of TAPVR was done under mild hypothermic cardiopulmonary bypass (CPB) using esmolol, an ultra short-acting beta-blocker to obtain good operative field without aortic-cross clamping. esmolol 186-193 TAPVR1 Homo sapiens 113-118 8484510-9 1993 During one propofol anesthetic, an esmolol infusion (100 micrograms.kg-1 x min-1) was started 10 min before stimulation to determine whether this agent would blunt the pupillary response. esmolol 35-42 CD59 molecule (CD59 blood group) Homo sapiens 75-80 7612051-0 1995 Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. esmolol 52-59 adrenoceptor beta 1 Homo sapiens 0-19 7915067-5 1994 Plasma catecholamines, atrial natriuretic factor, and aldosterone levels as well as plasma renin activity were identically influenced by esmolol and gallopamil, respectively. esmolol 137-144 renin Homo sapiens 91-96 7957532-0 1994 Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties. esmolol 0-7 adrenoceptor beta 1 Homo sapiens 41-60 7957532-2 1994 Up to a rate of infusion of esmolol of 500 micrograms.kg-1 BW.min-1 there was a maximal beta 1-receptor occupancy of 84.7% while beta 2-receptor occupancy was below the detection limit; confirming the beta 1 selectivity of esmolol. esmolol 28-35 CD59 molecule (CD59 blood group) Homo sapiens 62-67 7957532-2 1994 Up to a rate of infusion of esmolol of 500 micrograms.kg-1 BW.min-1 there was a maximal beta 1-receptor occupancy of 84.7% while beta 2-receptor occupancy was below the detection limit; confirming the beta 1 selectivity of esmolol. esmolol 28-35 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 88-94 7957532-2 1994 Up to a rate of infusion of esmolol of 500 micrograms.kg-1 BW.min-1 there was a maximal beta 1-receptor occupancy of 84.7% while beta 2-receptor occupancy was below the detection limit; confirming the beta 1 selectivity of esmolol. esmolol 28-35 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 129-135 7957532-2 1994 Up to a rate of infusion of esmolol of 500 micrograms.kg-1 BW.min-1 there was a maximal beta 1-receptor occupancy of 84.7% while beta 2-receptor occupancy was below the detection limit; confirming the beta 1 selectivity of esmolol. esmolol 28-35 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 201-207 7957532-2 1994 Up to a rate of infusion of esmolol of 500 micrograms.kg-1 BW.min-1 there was a maximal beta 1-receptor occupancy of 84.7% while beta 2-receptor occupancy was below the detection limit; confirming the beta 1 selectivity of esmolol. esmolol 223-230 CD59 molecule (CD59 blood group) Homo sapiens 62-67 1346371-1 1992 The antiarrhythmic effect of esmolol, a selective beta 1 adrenoreceptor blocker, was evaluated in the presence of epinephrine induced arrhythmias in dogs (n = 6). esmolol 29-36 adrenoceptor beta 1 Canis lupus familiaris 50-71 1682112-3 1991 Esmolol infusion (8 to 24 mg/min) produced large decreases in heart rate (84 +/- 2 to 69 +/- 2 beats/min, p less than 0.01) and SBP (124 +/- 3 to 106 +/- 3 mm Hg, p less than 0.01). esmolol 0-7 selenium binding protein 1 Homo sapiens 128-131 1681842-2 1991 A mean infusion rate of esmolol 50.5 micrograms kg-1 min-1 resulted in a decrease in mean arterial pressure to 63 mm Hg and heart rate to 99 beat min-1 and was associated with excellent surgical conditions. esmolol 24-31 CD59 molecule (CD59 blood group) Homo sapiens 53-58 1681842-2 1991 A mean infusion rate of esmolol 50.5 micrograms kg-1 min-1 resulted in a decrease in mean arterial pressure to 63 mm Hg and heart rate to 99 beat min-1 and was associated with excellent surgical conditions. esmolol 24-31 CD59 molecule (CD59 blood group) Homo sapiens 146-151 1972334-2 1990 Twenty patients scheduled for aorto-coronary bypass grafting suffering from tachycardia (heart rate (HR) greater than 100 beat min-1) were treated by infusion of esmolol, an ultra-short acting, selective beta 1-blocker. esmolol 162-169 CD59 molecule (CD59 blood group) Homo sapiens 127-132 1683818-7 1991 Esmolol was less effective in controlling blood pressure, but, in combination with low-dose narcotic, esmolol suppressed the SBP response to tracheal intubation. esmolol 102-109 selenium binding protein 1 Homo sapiens 125-128 1975995-1 1990 We evaluated the clinical effectiveness of esmolol, an ultra-short-acting beta 1-adrenergic receptor blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT). esmolol 43-50 adrenoceptor beta 1 Homo sapiens 74-100 34136985-3 2021 The current study was conducted to investigate the cytotoxic and apoptotic effects of beta-1 selective esmolol, beta-2 selective ICI-118,551, and non-selective nadolol blockers on the cancerous and healthy lung cells. esmolol 103-110 BCL2 related protein A1 Homo sapiens 86-92 1688693-3 1990 Esmolol, an ultrashort-acting beta 1-selective antagonist, controlled her multiple dysrhythmias and symptoms of sympathetic nervous system hyperstimulation. esmolol 0-7 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 30-36 34280895-14 2021 Children with PCC/PG and other comorbidity like asthma may particularly benefit from the use of esmolol due to no or less side effects on airway resistance and the advantage of rapid titration of the medication compared to other beta-blockers. esmolol 96-103 crystallin gamma D Homo sapiens 14-17 34140891-6 2021 Meanwhile, our analysis found that, esmolol could decrease HR (SMD: -1.70; 95% CI: (-2.24-(-1.17)), cTnI (SMD: -1.61; 95% CI: (-2.06-(-1.16)) compared with standard treatment. esmolol 36-43 troponin I3, cardiac type Homo sapiens 100-104 34136985-7 2021 Esmolol was found to be the most ineffective blocker and the increases in Bcl-2 protein levels were appeared to be effective in resistance to this drug. esmolol 0-7 BCL2 apoptosis regulator Homo sapiens 74-79 35066509-9 2022 There were lower levels of C-reactive protein at 12 and 24 h in the esmolol arm, as well as a statistically significant difference in trend over time between groups. esmolol 68-75 C-reactive protein Homo sapiens 27-45 35066509-13 2022 Esmolol was associated with decreased levels of C-reactive protein over 24 h. TRIAL REGISTRATION: www.clinicaltrials.gov. esmolol 0-7 C-reactive protein Homo sapiens 48-66 32412904-0 2020 Esmolol inhibits inflammation and apoptosis in the intestinal tissue via the overexpression of NF-kappaB-p65 in the early stage sepsis rats. esmolol 0-7 synaptotagmin 1 Rattus norvegicus 105-108 2568099-3 1989 Esmolol, the beta-1 adrenoceptor blocking agent was successfully used to control the thyrotoxic state. esmolol 0-7 adrenoceptor beta 1 Homo sapiens 13-32 2478807-12 1989 Conversely, preliminary data suggest that a beta-adrenergic antagonist, esmolol, causes a slowing of isovolumic myocardial relaxation. esmolol 72-79 amyloid beta precursor protein Homo sapiens 42-48 2894187-1 1988 Hypotension has been the most frequently reported adverse reaction associated with infusion of the beta 1-adrenergic receptor antagonist esmolol. esmolol 137-144 adrenoceptor beta 1 Canis lupus familiaris 99-125 3719434-4 1986 The benzoylcholine hydrolysis rates in the plasma of ten patients who received an esmolol infusion of 500 micrograms.kg-1.min-1 for 4 minutes were 58.6 +/- 6.2 mumol.hr-1.ml-1 (mean +/- SE) before and 55.1 +/- 6.6 mumol.hr-1.ml-1 after the infusion. esmolol 82-89 CD59 molecule (CD59 blood group) Homo sapiens 122-127 34980284-6 2022 After 1 h of treatment with esmolol, patients had a significant increase in Pcc (31.4 vs. 36.7 mmHg, P < 0.01). esmolol 28-35 crystallin gamma D Homo sapiens 76-79 34980284-10 2022 CONCLUSION: Patients with septic shock whose heart rate is greater than 95 beats/min after hemodynamic optimization were treated with esmolol, which could effectively control heart rate and reduce CI, as well as improve Pcc and increase the difference between Pcc and Pmsf (known as "vascular waterfall" phenomenon), without affecting MAP, CVP, Pmsf and arteriovenous vascular resistance, and improve the balance of oxygen supply and demand in the body. esmolol 134-141 crystallin gamma D Homo sapiens 220-223 34980284-10 2022 CONCLUSION: Patients with septic shock whose heart rate is greater than 95 beats/min after hemodynamic optimization were treated with esmolol, which could effectively control heart rate and reduce CI, as well as improve Pcc and increase the difference between Pcc and Pmsf (known as "vascular waterfall" phenomenon), without affecting MAP, CVP, Pmsf and arteriovenous vascular resistance, and improve the balance of oxygen supply and demand in the body. esmolol 134-141 crystallin gamma D Homo sapiens 260-263 2569849-0 1989 Esmolol for potentiation of nitroprusside-induced hypotension: impact on the cardiovascular, adrenergic, and renin-angiotensin systems in man. esmolol 0-7 renin Homo sapiens 109-114 2568748-4 1989 Esmolol, a unique cardioselective beta 1-adrenergic receptor blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy. esmolol 0-7 adrenoceptor beta 1 Homo sapiens 34-60 3768764-4 1986 Prior to induction esmolol produced significant decreases in heart rate (HR) (9.3 +/- 1.8 per cent) and rate-pressure product (RPP) (13.1 +/- 1.8 per cent), systolic blood pressure (SAP) (4.3 +/- 1.5 per cent) and mean arterial blood pressure (MAP) (1.7 +/- 2.0 per cent). esmolol 19-26 SH2 domain containing 1A Homo sapiens 182-185 3768764-5 1986 Increases in HR, SAP and RPP after intubation were approximately 50 per cent less in patients given esmolol compared to patients given placebo. esmolol 100-107 SH2 domain containing 1A Homo sapiens 17-20 3526984-9 1986 Infusion of esmolol at 200 micrograms X kg-1 X min-1 prevented tachycardia in response to intubation. esmolol 12-19 CD59 molecule (CD59 blood group) Homo sapiens 47-52 33831899-1 2021 BACKGROUND: Esmolol is a beta-1 selective blocker that has been shown to reduce postoperative pain. esmolol 12-19 BCL2 related protein A1 Homo sapiens 25-31 32978249-0 2020 BET 1: Esmolol-a novel adjunct to the ACLS algorithm? esmolol 7-14 Bet1 golgi vesicular membrane trafficking protein Homo sapiens 0-5 32412904-6 2020 RESULTS: The plasma levels of DAO and IL-10 levels were increased, whereas that of I-FABP and IL-6 were decreased in the sepsis rats after esmolol treatment, indicating that after the esmolol treatment, the intestinal inflammation and damages were remarkably reduced as compared to those in the normal saline treated sepsis rats. esmolol 139-146 fatty acid binding protein 2 Rattus norvegicus 83-89 32412904-6 2020 RESULTS: The plasma levels of DAO and IL-10 levels were increased, whereas that of I-FABP and IL-6 were decreased in the sepsis rats after esmolol treatment, indicating that after the esmolol treatment, the intestinal inflammation and damages were remarkably reduced as compared to those in the normal saline treated sepsis rats. esmolol 139-146 interleukin 6 Rattus norvegicus 94-98 32412904-6 2020 RESULTS: The plasma levels of DAO and IL-10 levels were increased, whereas that of I-FABP and IL-6 were decreased in the sepsis rats after esmolol treatment, indicating that after the esmolol treatment, the intestinal inflammation and damages were remarkably reduced as compared to those in the normal saline treated sepsis rats. esmolol 184-191 fatty acid binding protein 2 Rattus norvegicus 83-89 32412904-6 2020 RESULTS: The plasma levels of DAO and IL-10 levels were increased, whereas that of I-FABP and IL-6 were decreased in the sepsis rats after esmolol treatment, indicating that after the esmolol treatment, the intestinal inflammation and damages were remarkably reduced as compared to those in the normal saline treated sepsis rats. esmolol 184-191 interleukin 6 Rattus norvegicus 94-98 32412904-7 2020 NF-kappaB-p65 and Bcl-2 were highly expressed, but cleaved caspase-3 showed lower expression in the esmolol treated groups. esmolol 100-107 caspase 3 Rattus norvegicus 59-68 32412904-9 2020 Western blotting data indicated that the esmolol treatment inhibited the inflammation and apoptosis in the intestinal tissue due to the overexpression of NF-kappaB-p65 in the celiac sepsis rats. esmolol 41-48 synaptotagmin 1 Rattus norvegicus 164-167 32412904-11 2020 CONCLUSION: Esmolol can suppress inflammation and apoptosis in the intestinal tissue via the overexpression of NF-kappa B-p65 in the early stage sepsis rats. esmolol 12-19 synaptotagmin 1 Rattus norvegicus 122-125 31885916-5 2019 In the second experimental study, the effect of the beta-blocker esmolol was examined in CLP-P (group CLP-PE vs. CLP-P; n = 5 in each group). esmolol 65-72 caseinolytic mitochondrial matrix peptidase proteolytic subunit Mus musculus 89-94 31832629-3 2020 In this work, a novel capillary electrophoresis method using the ionic liquid 3-methyl-1-(3-sulfopropyl)-1H-imidazol-3-ium lactobionate (MSI-LA) as a chiral selector was developed for the enantioseparation of propranolol, metoprolol, bisoprolol, esmolol, atenolol, sotalol, terbutaline and clenbuterol. esmolol 246-253 RB binding protein 4, chromatin remodeling factor Homo sapiens 137-140 31514219-3 2019 Therefore, heart rate control may be necessary to prevent cardiovascular events.Esmolol and landiolol as ultrashort and rapid acting highly selective beta 1 -adrenergic blockers are of particular interest in the prevention and management of cardiac arrhythmias. esmolol 80-87 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 150-156 29554644-4 2018 Molecular modeling study was performed to confirm the binding of iodinated esmolol to beta1-adrenergic receptor. esmolol 75-82 adrenergic receptor, beta 1 Mus musculus 86-111 31060374-7 2019 RESULTS: At sea level, compared with baseline (14.8+-3.0 ) LV twist was reduced with esmolol (11.2+-3.3 ; P=0.007) and augmented during hypoxia (19.6+-4.9 ; P<0.001), whereas esmolol+hypoxia augmented twist compared with esmolol alone (16.5+-3.3 ; P<0.001). esmolol 85-92 S13 erythroblastosis (avian) oncogene homolog Homo sapiens 12-15 31060374-7 2019 RESULTS: At sea level, compared with baseline (14.8+-3.0 ) LV twist was reduced with esmolol (11.2+-3.3 ; P=0.007) and augmented during hypoxia (19.6+-4.9 ; P<0.001), whereas esmolol+hypoxia augmented twist compared with esmolol alone (16.5+-3.3 ; P<0.001). esmolol 178-185 S13 erythroblastosis (avian) oncogene homolog Homo sapiens 12-15 31060374-7 2019 RESULTS: At sea level, compared with baseline (14.8+-3.0 ) LV twist was reduced with esmolol (11.2+-3.3 ; P=0.007) and augmented during hypoxia (19.6+-4.9 ; P<0.001), whereas esmolol+hypoxia augmented twist compared with esmolol alone (16.5+-3.3 ; P<0.001). esmolol 178-185 S13 erythroblastosis (avian) oncogene homolog Homo sapiens 12-15 31023764-1 2019 INTRODUCTION AND AIMS: Esmolol is an ultra-short-acting beta1 antagonist that has been shown to attenuate the corrected QT (QTc) interval prolongation associated with laryngoscopy and endotracheal intubation (LTI). esmolol 23-30 BCL2 related protein A1 Homo sapiens 56-61 30827308-15 2019 CONCLUSIONS: beta1 receptor blocker esmolol may inhibit myocardial inflammatory response in sepsis adult rats through TLR4/NF-KappaB signaling pathway, thereby alleviating sepsis-induced myocardial injury. esmolol 36-43 toll-like receptor 4 Rattus norvegicus 118-122 29600897-3 2018 Healthy men (age: 25 +- 1 yr, n = 11) received intravenous esmolol (beta1-adrenergic receptor antagonist) or volume-matched saline in a double-blind, randomized crossover study and were exposed to poikilocapnic hypoxia, isocapnic hypoxia, and hypercapnic hypoxia. esmolol 59-66 adrenoceptor beta 1 Homo sapiens 68-93 30234542-10 2019 RESULTS: At 24 hours after the operation, the ESM group had less lung edema and lower expression of the proinflammatory biomarkers tumor necrosis factor (TNF) and interleukin (IL)-1 compared to the CON group for both lung lobes. esmolol 46-49 tumor necrosis factor Sus scrofa 131-152 30234542-10 2019 RESULTS: At 24 hours after the operation, the ESM group had less lung edema and lower expression of the proinflammatory biomarkers tumor necrosis factor (TNF) and interleukin (IL)-1 compared to the CON group for both lung lobes. esmolol 46-49 tumor necrosis factor Sus scrofa 154-157 29394143-4 2018 We hypothesized that beta1-adrenergic receptor blockade (esmolol infusion) exacerbates the negative effects of hypothermia on active myocardial motions, affecting both systolic and diastolic LV function. esmolol 57-64 adrenoceptor beta 1 Homo sapiens 21-46 29394143-14 2018 Beta1-adrenergic receptor blockade (esmolol) exacerbates the negative effects of hypothermia on active myocardial contraction and relaxation. esmolol 36-43 adrenoceptor beta 1 Homo sapiens 0-25 29554644-7 2018 The evidenced selectivity of the radioiodinated esmolol to beta1-adrenoceptor was confirmed by prior injection of cold esmolol. esmolol 48-55 adrenergic receptor, beta 1 Mus musculus 59-77 29665297-2 2018 In this study, we examined the effects of the fast-acting, beta1 selective blocker esmolol on systemic hemodynamics and leg muscle O2 saturation (near infrared spectroscopy, NIRS) during submaximal leg ergometry. esmolol 83-90 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 59-64 29670896-0 2018 Short-Term Treatment with Esmolol Reverses Left Ventricular Hypertrophy in Adult Spontaneously Hypertensive Rats via Inhibition of Akt/NF-kappaB and NFATc4. esmolol 26-33 AKT serine/threonine kinase 1 Rattus norvegicus 131-134 29670896-0 2018 Short-Term Treatment with Esmolol Reverses Left Ventricular Hypertrophy in Adult Spontaneously Hypertensive Rats via Inhibition of Akt/NF-kappaB and NFATc4. esmolol 26-33 nuclear factor of activated T-cells 4 Rattus norvegicus 149-155 29670896-9 2018 Short-term treatment with esmolol reverses LVH in aged SHRs by downregulation of Akt/NF-kappaB and NFATc4 activity. esmolol 26-33 AKT serine/threonine kinase 1 Rattus norvegicus 81-84 29670896-9 2018 Short-term treatment with esmolol reverses LVH in aged SHRs by downregulation of Akt/NF-kappaB and NFATc4 activity. esmolol 26-33 nuclear factor of activated T-cells 4 Rattus norvegicus 99-105 26826640-0 2016 Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol? esmolol 93-100 dimethylarginine dimethylaminohydrolase 1 Homo sapiens 14-18 27125844-1 2017 We hypothesized that the cardioselective beta1-adrenoreceptor antagonist esmolol would improve maximal apnea duration in elite breath-hold divers. esmolol 73-80 adrenoceptor beta 1 Homo sapiens 41-61 27882105-12 2016 In conclusion, preoperative esmolol may be an effective and safe measure of myocardial protection for patients who undergo elective cardiac surgeries under CBP. esmolol 28-35 CREB binding protein Homo sapiens 156-159 27451411-2 2016 Esmolol was introduced some three decades ago as a short-acting beta1-selective antagonist. esmolol 0-7 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 64-69 27451411-8 2016 If cells were incubated for >=24 hours in the presence of >=1 muM esmolol, the levels of beta1-adrenergic-but not of beta2-adrenergic-receptors increased. esmolol 72-79 latexin Homo sapiens 68-71 27451411-8 2016 If cells were incubated for >=24 hours in the presence of >=1 muM esmolol, the levels of beta1-adrenergic-but not of beta2-adrenergic-receptors increased. esmolol 72-79 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 95-100 27269252-11 2016 Furthermore, esmolol reduced SAP-induced plasma amylase activity (p = 0.02), blunted the expression of TNF-alpha (p = 0.003) and IL-6 (p < 0.001), and decreased pancreas/lung MPO activities. esmolol 13-20 tumor necrosis factor Rattus norvegicus 103-112 27269252-11 2016 Furthermore, esmolol reduced SAP-induced plasma amylase activity (p = 0.02), blunted the expression of TNF-alpha (p = 0.003) and IL-6 (p < 0.001), and decreased pancreas/lung MPO activities. esmolol 13-20 interleukin 6 Rattus norvegicus 129-133 27269252-11 2016 Furthermore, esmolol reduced SAP-induced plasma amylase activity (p = 0.02), blunted the expression of TNF-alpha (p = 0.003) and IL-6 (p < 0.001), and decreased pancreas/lung MPO activities. esmolol 13-20 myeloperoxidase Rattus norvegicus 178-181 26826640-10 2016 Therefore, we propose that the ADMA/DDAH/NO pathway could modulate early regression of LVH with esmolol. esmolol 96-103 dimethylarginine dimethylaminohydrolase 1 Homo sapiens 36-40 28595458-3 2018 D8 and D9 exhibited a slightly higher anti-myocardial injury (5.78, 7.46 muM) activity compared with esmolol (8.12 muM). esmolol 101-108 latexin Homo sapiens 115-118 28035016-1 2017 Despite its widespread clinical use, the beta1-adrenergic receptor antagonist esmolol hydrochloride is not commonly used in human physiology research, and the effective dose of esmolol (compared with the nonselective beta-blocker propranolol) is unclear. esmolol 78-85 adrenoceptor beta 1 Homo sapiens 41-66 28035016-7 2017 Collectively, our data indicate that infusion of ~160 mg of esmolol (range 110-200 mg in the 5 min before exercise) acutely and selectively blocks beta1-receptors in healthy humans. esmolol 60-67 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 147-152 28035016-10 2017 Collectively, our data indicate that infusion of ~160 mg of esmolol (range 110-200 mg in the 5 min before exercise) acutely and selectively blocks beta1-adrenergic receptors. esmolol 60-67 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 147-152 23411610-1 2015 Perioperative tachycardia and hypertension are often treated with esmolol, a short-acting beta1-adrenoceptor antagonist. esmolol 66-73 adrenoceptor beta 1 Rattus norvegicus 90-108 26316443-10 2016 Esmolol infusion reversed LPS-induced impairment of cardiac function and reduced LPS-induced myocardial apoptosis that is associated with c-Jun N-terminal kinase (JNK) and p38 activation. esmolol 0-7 mitogen-activated protein kinase 8 Mus musculus 138-161 26316443-10 2016 Esmolol infusion reversed LPS-induced impairment of cardiac function and reduced LPS-induced myocardial apoptosis that is associated with c-Jun N-terminal kinase (JNK) and p38 activation. esmolol 0-7 mitogen-activated protein kinase 8 Mus musculus 163-166 26316443-10 2016 Esmolol infusion reversed LPS-induced impairment of cardiac function and reduced LPS-induced myocardial apoptosis that is associated with c-Jun N-terminal kinase (JNK) and p38 activation. esmolol 0-7 mitogen-activated protein kinase 14 Mus musculus 172-175 26316443-11 2016 CONCLUSIONS: These data demonstrate that cardioprotection provided by esmolol infusion during LPS insult is associated with antiapoptotic effects and regulation of JNK and p38 activations. esmolol 70-77 mitogen-activated protein kinase 8 Mus musculus 164-167 26316443-11 2016 CONCLUSIONS: These data demonstrate that cardioprotection provided by esmolol infusion during LPS insult is associated with antiapoptotic effects and regulation of JNK and p38 activations. esmolol 70-77 mitogen-activated protein kinase 14 Mus musculus 172-175 25990895-2 2015 The submicron, non-porous, cyclodextrin-based chiral stationary phases (sub_mum-CSP2) exhibited excellent chiral recognition of a wide range of analytes including clenbuterol hydrochloride, mexiletine hydrochloride, chlorpheniramine maleate, esmolol hydrochloride, and metoprolol tartrate. esmolol 242-263 regulator of calcineurin 2 Homo sapiens 80-84 25790148-15 2015 CONCLUSION: The combination of milrinone, esmolol and vasopressin decreased cardiac injury compared with vasopressin alone. esmolol 42-49 arginine vasopressin Homo sapiens 105-116 24803523-10 2015 In addition, the CRP levels on postoperative day 1 were lower in the esmolol-treated groups, in a dose-dependent manner. esmolol 69-76 C-reactive protein Homo sapiens 17-20 24803523-12 2015 Treatment with esmolol decreased the inflammatory response and CRP production in a dose-dependent manner. esmolol 15-22 C-reactive protein Homo sapiens 63-66 26316443-3 2016 Increasing evidence suggests the anti-inflammatory role of beta1-adrenergic blocker, esmolol, during lethal endotoxemia. esmolol 85-92 hemoglobin, beta adult major chain Mus musculus 59-64 24941896-7 2015 Recently, esmolol, a short-time acting beta1-adrenoceptor blocker titrated to decrease heart rate below 95 beats/min was shown to exert beneficial effects in a monocentric randomized clinical trial including selected septic patients. esmolol 10-17 adrenoceptor beta 1 Homo sapiens 39-57 23873274-3 2013 The purpose of the present pilot study was to investigate the effects of reducing heart rate to less than 95 beats per minute in patients with septic shock using the beta-1 adrenoceptor blocker, esmolol, with specific focus on systemic hemodynamics and the microcirculation. esmolol 195-202 adrenoceptor beta 1 Homo sapiens 166-185 26121122-9 2015 Five prospective studies (two randomized) assessed the hemodynamic effects of the beta1-blocker esmolol. esmolol 96-103 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 82-87 23994276-8 2013 Surprisingly, esmolol significantly attenuated the arrhythmogenic effect of D-SP throughout the MI, beyond the time span of esmolol action, during which a significant up-regulation of the NK1-R (by 19%, P<0.05) was detected. esmolol 14-21 tachykinin receptor 1 Rattus norvegicus 188-193 23384300-2 2013 BACKGROUND: Esmolol, an ultra-short acting beta 1-adrenoceptor blocker, reduces myocardial injury in adult cardiac operations. esmolol 12-19 adrenoceptor beta 1 Homo sapiens 43-62 23902616-5 2013 The adrenergic beta-1 antagonist esmolol was injected through central venous catheter to reduce heart rate by 20% from baseline. esmolol 33-40 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 15-21 23384300-7 2013 Values of heart rate 10 min after induction, 2 min before institution of CPB, 2 min after completion of CPB, and at the end of surgery were significantly lower in the esmolol group; however, mean arterial pressure, CPB time, cross-clamp time, and the rate of heart spontaneous rebeating were not statistically different between two groups. esmolol 167-174 carboxypeptidase B2 Homo sapiens 73-79 23114278-0 2013 The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting beta(1) adrenergic receptor antagonist esmolol in healthy individuals. esmolol 133-140 adrenoceptor beta 1 Homo sapiens 21-26 23114278-0 2013 The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting beta(1) adrenergic receptor antagonist esmolol in healthy individuals. esmolol 133-140 adrenoceptor beta 1 Homo sapiens 94-121 23114278-3 2013 The aim of this study was to determine the effect of the Arg389Gly polymorphism on the inhibition of exercise-induced tachycardia by esmolol, an ultra-short-acting intravenously administered beta1AR antagonist. esmolol 133-140 adrenoceptor beta 1 Homo sapiens 191-198 22583856-0 2012 Neuroprotective effects of selective beta-1 adrenoceptor antagonists, landiolol and esmolol, on transient forebrain ischemia in rats; a dose-response study. esmolol 84-91 adrenoceptor beta 1 Rattus norvegicus 37-56 22530954-5 2012 We then show that the non-conserved K347 (6.58) appears to facilitate in guiding Esmolol to the extracellular surface via hydrogen bonds in the beta(1) adrenoceptor. esmolol 81-88 adrenoceptor beta 1 Homo sapiens 144-164 22583856-8 2012 Neurological deficit scores at 1, 4 and 7 days were lower, and the number of intact neurons in CA1 hippocampal region was larger in the rats treated with esmolol and landiolol after ischemia, compared with saline-treated rats (P<0.05), whereas no difference was found among different doses of esmolol and landiolol. esmolol 154-161 carbonic anhydrase 1 Rattus norvegicus 95-98 20877702-2 2010 Esmolol is an ultra short acting cardioselective beta1-adrenergic receptor antagonist, and it has been successfully used for perioperative sympatholysis and it reduces the opioid requirement during total intravenous anesthesia. esmolol 0-7 adrenoceptor beta 1 Homo sapiens 49-74 21843205-2 2012 One of these agents is esmolol (ESM) which is a short-acting selective beta-1 adrenergic receptor antagonist and its overdose causes diastolic ventricular arrest. esmolol 23-30 adrenoceptor beta 1 Rattus norvegicus 71-97 21434894-8 2011 Esmolol attenuated the rise in mean arterial pressure in men (5 9% +- 3 6 CI(95%), P = 0 6) but not in women (14 3% +- 3 2 CI(95%), P = 0 007). esmolol 0-7 H3.7 histone (putative) Homo sapiens 83-90 21539458-7 2011 BNP > 141 pg/ml at admission had a 95% predictive value for subsequent withdrawal of esmolol. esmolol 88-95 natriuretic peptide B Homo sapiens 0-3 21539458-9 2011 CONCLUSIONS: In conclusion, BNP measurement in combination with systolic blood pressure and 2D echocardiography may identify patients with non-ST elevation acute coronary syndromes at high risk for adverse events during esmolol infusion. esmolol 220-227 natriuretic peptide B Homo sapiens 28-31 21847651-8 2011 Plasma TNF-alpha was not detectable in either group, while intraperitoneal fluid TNF-alpha level was elevated in the control group but significantly depressed in the esmolol group (16.8 +- 10.7 versus 5.4 +- 7.1 pg/ml, P < 0.05). esmolol 166-173 tumor necrosis factor Rattus norvegicus 81-90 21562974-1 2011 INTRODUCTION: The present study determined whether late-ischemia/early reperfusion therapy with the beta(1)-adrenergic receptor (AR) blocker esmolol and phosphodiesterase III inhibitor milrinone reduced left ventricular (LV) myocardial infarct size (IS). esmolol 141-148 adrenoceptor beta 1 Rattus norvegicus 100-127 21562974-1 2011 INTRODUCTION: The present study determined whether late-ischemia/early reperfusion therapy with the beta(1)-adrenergic receptor (AR) blocker esmolol and phosphodiesterase III inhibitor milrinone reduced left ventricular (LV) myocardial infarct size (IS). esmolol 141-148 adrenoceptor beta 1 Rattus norvegicus 129-131 21562974-5 2011 LV-IS-reduction induced by esmolol + milrinone was eliminated in the presence of protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-inhibitor (AKT 1/2 kinase inhibitor). esmolol 27-34 calmodulin 2, pseudogene 1 Rattus norvegicus 118-123 21562974-5 2011 LV-IS-reduction induced by esmolol + milrinone was eliminated in the presence of protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-inhibitor (AKT 1/2 kinase inhibitor). esmolol 27-34 AKT serine/threonine kinase 1 Rattus norvegicus 128-131 21562974-5 2011 LV-IS-reduction induced by esmolol + milrinone was eliminated in the presence of protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-inhibitor (AKT 1/2 kinase inhibitor). esmolol 27-34 AKT serine/threonine kinase 1 Rattus norvegicus 143-146 21562974-7 2011 This cell protective effect by esmolol + milrinone was abrogated in the presence of PKA-inhibitor or Akt-inhibitor. esmolol 31-38 AKT serine/threonine kinase 1 Rattus norvegicus 101-104 21562974-14 2011 CONCLUSIONS: Late-ischemia/early reperfusion therapy with esmolol + milrinone additively reduces LV-IS associated with robust activation of myocardial PKA and subsequent Akt-antiapoptotic pathway. esmolol 58-65 AKT serine/threonine kinase 1 Rattus norvegicus 170-173 20103544-0 2010 Esmolol and landiolol, selective beta1-adrenoreceptor antagonists, provide neuroprotection against spinal cord ischemia and reperfusion in rats. esmolol 0-7 adrenoceptor beta 1 Rattus norvegicus 33-53 19581034-1 2009 OBJECTIVES: The aim of the study was to investigate the effect on calcium cycling protein and electrical restitution of beta(1)-adrenergic receptor antagonist esmolol administered during cardiopulmonary resuscitation in the porcine ventricular fibrillation model. esmolol 159-166 adrenoceptor beta 1 Sus scrofa 120-147 19336536-6 2009 Peak plasma BNP concentrations were significantly higher in control patients [293 (98) pg ml(-1)] than in esmolol [118 (71) pg ml(-1)] and in esmolol+enoximone-treated patients [78 (21) pg ml(-1)]. esmolol 106-113 natriuretic peptide B Homo sapiens 12-15 19336536-6 2009 Peak plasma BNP concentrations were significantly higher in control patients [293 (98) pg ml(-1)] than in esmolol [118 (71) pg ml(-1)] and in esmolol+enoximone-treated patients [78 (21) pg ml(-1)]. esmolol 142-149 natriuretic peptide B Homo sapiens 12-15 19150530-12 2009 The ultra-short-acting beta-1 selective adrenergic antagonists esmolol and landiolol can be safely used perioperatively in patients with airway hyperreactivity. esmolol 63-70 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 23-29 19122550-1 2009 BACKGROUND AND OBJECTIVE: It is known that esmolol, a short-acting beta1-blocker, reduces anaesthetic requirement. esmolol 43-50 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 67-72 15966380-3 2005 METHODS: Propranolol (n=22) or esmolol (n= 29) was given intravenously when the heart rate was above 100 beats x min(-1) during emergence from anesthesia. esmolol 31-38 CD59 molecule (CD59 blood group) Homo sapiens 113-119 18270676-7 2008 Peak plasma BNP concentrations were significantly increased in both groups but the highest values were measured in the esmolol alone group. esmolol 119-126 natriuretic peptide B Homo sapiens 12-15 16953590-2 2006 The reactions of PheH and TrpH have been investigated with [4-(2)H]-, [3,5-(2)H(2)]-, and (2)H(5)-phenylalanine as substrates. esmolol 60-66 phenylalanine hydroxylase Rattus norvegicus 17-21 16627864-9 2006 Blockade of the HO pathway after preconditioning and the combined pretreatment with dobutamine and esmolol decreased PDR(ICG) (Dob/SnMP/Shock: 12.6 +/- 4.24%/min, p = 0.011; Dob/Esmolol/Shock: 10.2 +/- 4.34%/min, p = 0.008). esmolol 99-106 PDR Homo sapiens 117-125 16215384-1 2005 OBJECTIVE: Since beta-blocker therapy is known to be effective in patients with an injured heart, such as infarction, we designed the present study to examine the protective effects of infusion of the beta1-selective blocker esmolol on myocardial function in peritonitis-induced septic rats using an isolated working heart preparation. esmolol 225-232 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 201-206 16215384-7 2005 MEASUREMENTS AND MAIN RESULTS: Esmolol infusion did not cause an elevation of arterial lactate levels but reduced tumor necrosis factor-alpha concentrations vs. the control group (p < .05). esmolol 31-38 tumor necrosis factor Rattus norvegicus 114-141 15966380-6 2005 The total dose of esmolol was 32.8 +/- 16.2 mg, which decreased the heart rate significantly from 110.0+/-13.9 to 84.9+/-10.7 beats x min(-1). esmolol 18-25 CD59 molecule (CD59 blood group) Homo sapiens 134-140 16038270-5 2005 Esmolol, a beta1-adrenoceptor antagonist blocked these effects of isoprenaline and autoantibodies. esmolol 0-7 adrenoceptor beta 1 Homo sapiens 11-29 15728061-0 2005 The short-acting beta1-adrenoceptor antagonists esmolol and landiolol suppress the bispectral index response to tracheal intubation during sevoflurane anesthesia. esmolol 48-55 adrenoceptor beta 1 Homo sapiens 17-35 15728061-1 2005 In this randomized, double-blind, controlled study, we tested the hypothesis that the short-acting beta(1)-adrenoceptor antagonists esmolol and landiolol suppress hemodynamic changes and bispectral index (BIS) increases, both of which are induced by tracheal intubation under general anesthesia with sevoflurane alone. esmolol 132-139 adrenoceptor beta 1 Homo sapiens 99-119 12453930-2 2002 We explored whether adding esmolol, a short-acting beta(1)-adrenoceptor antagonist, to propofol anaesthesia modified the bispectral index (BIS) during induction of anaesthesia and orotracheal intubation. esmolol 27-34 adrenoceptor beta 1 Homo sapiens 51-71 14638923-4 2003 After a 75-min baseline period, seven subjects received a continuous intravenous infusion of the short-acting beta1-adrenergic receptor blocker esmolol for 105 min. esmolol 144-151 adrenoceptor beta 1 Homo sapiens 110-135 12460877-3 2002 METHODS AND RESULTS: We investigated the consequences of short-term intravenous administration of an alpha-1 adrenergic agonist, phenylephrine, and a beta-1 adrenergic antagonist, esmolol, in 14 patients with POTS aged 13 to 19 years. esmolol 180-187 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 150-156 12565117-4 2002 We concluded that the beta(1) selective, ultra-short acting beta-blocker, esmolol, can be used intraoperatively when both conditions are present. esmolol 74-81 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 22-29